Ryvent (Carbinoxamine Maleate) Patent Expiration, LOE Window & CMS Spending

Ryvent (Carbinoxamine Maleate) by Carwin Associat: Off-Patent Genericized (AB Competition), 2 AB generics, $1.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCarwin Associat
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$1.9M
2024 Medicare Part D Spend$440K
2024 Medicaid Spend$1.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel